WO2001078786A3 - High affinity peptide-containing nanoparticles - Google Patents

High affinity peptide-containing nanoparticles Download PDF

Info

Publication number
WO2001078786A3
WO2001078786A3 PCT/US2001/012093 US0112093W WO0178786A3 WO 2001078786 A3 WO2001078786 A3 WO 2001078786A3 US 0112093 W US0112093 W US 0112093W WO 0178786 A3 WO0178786 A3 WO 0178786A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
high affinity
containing nanoparticles
affinity peptide
peptide moieties
polymeric nanoparticles
Prior art date
Application number
PCT/US2001/012093
Other languages
French (fr)
Other versions
WO2001078786A2 (en )
Inventor
Stephen E Barry
Dominic Casenas
Rachel Decor
Andrew A Goodwin
Kevin Lindquist
Original Assignee
Alnis Biosciences Inc
Stephen E Barry
Dominic Casenas
Rachel Decor
Andrew A Goodwin
Kevin Lindquist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer

Abstract

The present invention is directed to polymeric nanoparticles functionalized with two or more peptide moieties that possess high affinity to biomolecular targets, the peptide moieties being covalently linked to the nanoparticle polymeric core structure, either directly or via a linker molecule. The invention is further directed to methods of synthesizing these polymeric nanoparticles and to the various applications for which they may be used.
PCT/US2001/012093 2000-04-14 2001-04-13 High affinity peptide-containing nanoparticles WO2001078786A3 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
US19776500 true 2000-04-14 2000-04-14
US60/197,765 2000-04-14
US22006100 true 2000-07-21 2000-07-21
US60/220,061 2000-07-21
US22053000 true 2000-07-24 2000-07-24
US60/220,530 2000-07-24
US23644800 true 2000-09-29 2000-09-29
US60/236,448 2000-09-29
US25689400 true 2000-12-18 2000-12-18
US25689500 true 2000-12-18 2000-12-18
US25681900 true 2000-12-18 2000-12-18
US60/256,894 2000-12-18
US60/256,985 2000-12-18
US60/256,819 2000-12-18
US26152001 true 2001-01-12 2001-01-12
US60/261,520 2001-01-12

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA 2406395 CA2406395A1 (en) 2000-04-14 2001-04-13 High affinity peptide-containing nanoparticles
JP2001576085A JP2004500438A (en) 2000-04-14 2001-04-13 High affinity of the peptide-containing nanoparticles
US10257455 US20040126900A1 (en) 2001-04-13 2001-04-13 High affinity peptide- containing nanoparticles
EP20010928507 EP1276507A2 (en) 2000-04-14 2001-04-13 High affinity peptide-containing nanoparticles

Publications (2)

Publication Number Publication Date
WO2001078786A2 true WO2001078786A2 (en) 2001-10-25
WO2001078786A3 true true WO2001078786A3 (en) 2002-08-15

Family

ID=27575157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012093 WO2001078786A3 (en) 2000-04-14 2001-04-13 High affinity peptide-containing nanoparticles

Country Status (3)

Country Link
EP (1) EP1276507A2 (en)
CA (1) CA2406395A1 (en)
WO (1) WO2001078786A3 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487720A1 (en) * 2002-06-03 2003-12-11 Alnis Biosciences, Inc. Therapeutic agent-containing polymeric nanoarticles
RU2006142851A (en) * 2004-05-05 2008-06-10 Фирмениш Са (Ch) Biodegradable grafted copolymers
US8231907B2 (en) 2006-03-21 2012-07-31 Morehouse School Of Medicine Nanoparticles for delivery of active agents
CN103665117B (en) * 2013-12-03 2015-07-01 南昌大学 Method for high-efficiency purification of water soluble nano silver particle-streptavidin conjugate
CN103665118B (en) * 2013-12-03 2015-11-25 南昌大学 Purification of the water-soluble iron oxide nanoparticles streptavidin-biotin conjugate method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904936A (en) * 1995-03-28 1999-05-18 Flamel Technologies Particles based on polyamino acid(s) and capable of being used as delivery vehicles for active principle(s) and method for preparing them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904936A (en) * 1995-03-28 1999-05-18 Flamel Technologies Particles based on polyamino acid(s) and capable of being used as delivery vehicles for active principle(s) and method for preparing them

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVIS S S: "Biomedical applications of nanotechnology - implications for drug targeting and gene therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 15, no. 6, 1 June 1997 (1997-06-01), pages 217 - 224, XP004064510, ISSN: 0167-7799 *
HARRIS E ET AL: "Preparation and in vitro characterisation of biodegradable cyclosporin-loaded micro- and nanoparticles", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 46, no. 1, 5 May 1997 (1997-05-05), pages 190, XP004055754, ISSN: 0168-3659 *
JAGUR-GRODZINSKI J: "Biomedical application of functional polymers", REACTIVE & FUNCTIONAL POLYMERS, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 39, no. 2, 15 February 1999 (1999-02-15), pages 99 - 138, XP004160680, ISSN: 1381-5148 *
LEMOINE D ET AL: "Polymeric nanoparticles as delivery system for influenza virus glycoproteins", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 54, no. 1, 1 June 1998 (1998-06-01), pages 15 - 27, XP004127852, ISSN: 0168-3659 *

Also Published As

Publication number Publication date Type
EP1276507A2 (en) 2003-01-22 application
CA2406395A1 (en) 2001-10-25 application
WO2001078786A2 (en) 2001-10-25 application

Similar Documents

Publication Publication Date Title
Tingaut et al. Cellulose nanocrystals and microfibrillated cellulose as building blocks for the design of hierarchical functional materials
US20070249805A1 (en) Clay-binding peptides and methods of use
WO2003074679A3 (en) Antibody optimization
WO2004055160A3 (en) Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry
Daima et al. Synergistic influence of polyoxometalate surface corona towards enhancing the antibacterial performance of tyrosine-capped Ag nanoparticles
Morozov Explicit formulae for one-, two-, three-and four-loop string amplitudes
Zhang et al. Benzoboroxole‐functionalized magnetic core/shell microspheres for highly specific enrichment of glycoproteins under physiological conditions
WO2003099843A3 (en) Peptide derivatives, and their use for the synthesis of silicon-based composite materials
DE202004019687U1 (en) Clear varnish containing fine particles of silver, useful particularly for coating wood to impart long-lasting antimicrobial properties
Lee et al. A bioinspired polymeric template for 1D assembly of metallic nanoparticles, semiconductor quantum dots, and magnetic nanoparticles
CA2459724A1 (en) Multi-use multimodal imaging chelates
WO2003031581A3 (en) Thioester-terminated water soluble polymers and method of modifying the n-terminus of a polypeptide therewith
Betancourt et al. Drug encapsulation within self-assembled microglobules formed by thermoresponsive supramolecules
Stephan et al. Pegylation of 1, 4, 8, 11-tetraazacyclotetradecane (cyclam) and its Cu (II) complexation
CA2296894A1 (en) Modified condensation polymers having azetidinium groups and containing polysiloxane moieties
Timin et al. Synthesis and application of silica hybrids grafted with new guanidine-containing polymers as highly effective adsorbents for bilirubin removal
WO2011156895A2 (en) Magnetic nanoparticles and uses thereof
WO2003078626A3 (en) A building block capable of transferring a functional entity
Gour et al. Controlling morphology of peptide‐based soft structures by covalent modifications
WO2005054262A1 (en) Phosphorylcholine group-containing compound and surface modifying agent composed of such compound
Nasiri et al. In vitro evaluation of actively targetable superparamagnetic nanoparticles to the folate receptor positive cancer cells
Khan et al. Adsorption and recovery of polyphenolic flavonoids using TiO2-functionalized mesoporous silica nanoparticles
Hao et al. Selective extraction of gallic acid in pomegranate rind using surface imprinting polymers over magnetic carbon nanotubes
Schadock-Hewitt et al. Head group-functionalized poly (ethyleneglycol)–lipid (PEG–lipid) surface modification for highly selective analyte extractions on capillary-channeled polymer (C-CP) fibers
Maier et al. Siderophores and mussel foot proteins: the role of catechol, cations, and metal coordination in surface adhesion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001255356

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2406395

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 576085

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001928507

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001928507

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10257455

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001928507

Country of ref document: EP